{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:42:49Z","timestamp":1794724969289,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573663"],"award-info":[{"award-number":["81573663"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573663"],"award-info":[{"award-number":["81573663"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011785","name":"Science and Technology Department of Guangxi Zhuang Autonomous","doi-asserted-by":"publisher","award":["AB16450008"],"award-info":[{"award-number":["AB16450008"]}],"id":[{"id":"10.13039\/501100011785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011785","name":"Science and Technology Department of Guangxi Zhuang Autonomous","doi-asserted-by":"publisher","award":["AB16450008"],"award-info":[{"award-number":["AB16450008"]}],"id":[{"id":"10.13039\/501100011785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-alcoholic fatty liver disease (NAFLD) has been shown to influence breast cancer progression, but the underlying mechanisms remain unclear. In this study, we investigated the impact of NAFLD on breast cancer tumor growth and cell viability through the potential mediator, hepatic fibroblast growth factor 21 (FGF21). Both peritumoral and systemic administration of FGF21 promoted breast cancer tumor growth, while FGF21 knockout attenuated the tumor-promoting effects of the high-fat diet. Mechanistically, exogenous FGF21 treatment enhanced the anti-apoptotic ability of breast cancer cells through STAT3 and Akt\/FoXO1 signaling pathways, and mitigated doxorubicin-induced cell death. Furthermore, we observed overexpression of FGF21 in tumor tissues from breast cancer patients, which was associated with poor prognosis. These findings suggest a novel role for FGF21 as an upregulated mediator in the context of NAFLD, promoting breast cancer development and highlighting its potential as a therapeutic target for cancer treatment.<\/jats:p>","DOI":"10.1038\/s41419-023-06386-8","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T08:02:32Z","timestamp":1705564952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21"],"prefix":"10.1038","volume":"15","author":[{"given":"Yue","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-5271","authenticated-orcid":false,"given":"Jianping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"6386_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA: Cancer J Clin"},{"key":"6386_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6386_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71:778\u201388.","journal-title":"Gut"},{"key":"6386_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2016.08.019","volume":"34","author":"R Bitzur","year":"2016","unstructured":"Bitzur R, Brenner R, Maor E, Antebi M, Ziv-Baran T, Segev S, et al. Metabolic syndrome, obesity, and the risk of cancer development. Eur J Intern Med. 2016;34:89\u201393.","journal-title":"Eur J Intern Med"},{"key":"6386_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679\u201389.","journal-title":"Hepatology"},{"key":"6386_CR6","doi-asserted-by":"publisher","first-page":"114658","DOI":"10.1016\/j.ejmech.2022.114658","volume":"241","author":"MZI Khan","year":"2022","unstructured":"Khan MZI, Uzair M, Nazli A, Chen JZ. An overview on estrogen receptors signaling and its ligands in breast cancer. Eur J Med Chem. 2022;241:114658.","journal-title":"Eur J Med Chem"},{"key":"6386_CR7","first-page":"163","volume":"19","author":"L Qian","year":"2021","unstructured":"Qian L, Zhang F, Yin M, Lei Q. Cancer metabolism and dietary interventions. Cancer Biol Med. 2021;19:163\u201374.","journal-title":"Cancer Biol Med"},{"key":"6386_CR8","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.molmet.2020.101138","volume":"44","author":"SO Jensen-Cody","year":"2021","unstructured":"Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: deciphering communication from the liver. Mol Metab. 2021;44:101138.","journal-title":"Mol Metab"},{"key":"6386_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","volume":"1492","author":"T Nishimura","year":"2000","unstructured":"Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492:203\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"6386_CR10","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.7150\/ijbs.76924","volume":"18","author":"Y Sui","year":"2022","unstructured":"Sui Y, Chen J. Hepatic FGF21: its emerging role in inter-organ crosstalk and cancers. Int J Biol Sci. 2022;18:5928\u201342.","journal-title":"Int J Biol Sci"},{"key":"6386_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","volume":"3","author":"KH Flippo","year":"2021","unstructured":"Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab. 2021;3:309\u201317.","journal-title":"Nat Metab"},{"key":"6386_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.tem.2021.08.008","volume":"32","author":"S Keipert","year":"2021","unstructured":"Keipert S, Ost M. Stress-induced FGF21 and GDF15 in obesity and obesity resistance. Trends Endocrinol Metab. 2021;32:904\u201315.","journal-title":"Trends Endocrinol Metab"},{"key":"6386_CR13","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3390\/biomedicines9121903","volume":"9","author":"TH Kim","year":"2021","unstructured":"Kim TH, Hong DG, Yang YM. Hepatokines and non-alcoholic fatty liver disease: linking liver pathophysiology to metabolism. Biomedicines. 2021;9:1903.","journal-title":"Biomedicines"},{"key":"6386_CR14","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/cancers11081154","volume":"11","author":"YE Kang","year":"2019","unstructured":"Kang YE, Kim JT, Lim MA, Oh C, Liu L, Jung SN, et al. Association between circulating fibroblast growth factor 21 and aggressiveness in thyroid cancer. Cancers (Basel). 2019;11:1154.","journal-title":"Cancers (Basel)"},{"key":"6386_CR15","doi-asserted-by":"publisher","first-page":"118875","DOI":"10.1016\/j.lfs.2020.118875","volume":"269","author":"X Yu","year":"2021","unstructured":"Yu X, Li Y, Jiang G, Fang J, You Z, Shao G, et al. FGF21 promotes non-small cell lung cancer progression by SIRT1\/PI3K\/AKT signaling. Life Sci. 2021;269:118875.","journal-title":"Life Sci"},{"key":"6386_CR16","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1158\/1538-7445.AM2015-1577","volume":"75","author":"ME Knott","year":"2015","unstructured":"Knott ME, Ranuncolo SM, Nu\u00f1ez M, Armanasco E, Puricelli LI, De Lorenzo MS. Abstract 1577: levels of fibroblast growth factor 21 (FGF21) in serum as diagnostic biomarker in patients with breast cancer. Cancer Res. 2015;75:1577\u20131577.","journal-title":"Cancer Res"},{"key":"6386_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/CBM-161507","volume":"18","author":"M Akyol","year":"2017","unstructured":"Akyol M, Alacacioglu A, Demir L, Kucukzeybek Y, Yildiz Y, Gumus Z, et al. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. Cancer Biomark: Sect A Dis Markers. 2017;18:441\u20139.","journal-title":"Cancer Biomark: Sect A Dis Markers"},{"key":"6386_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/nu9101072","volume":"9","author":"MA Van Herck","year":"2017","unstructured":"Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease\u2014a starter\u2019s guide. Nutrients. 2017;9:1072.","journal-title":"Nutrients"},{"key":"6386_CR19","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/oby.2004.160","volume":"12","author":"CC Hu","year":"2004","unstructured":"Hu CC, Qing K, Chen Y. Diet-induced changes in stearoyl-CoA desaturase 1 expression in obesity-prone and -resistant mice. Obes Res. 2004;12:1264\u201370.","journal-title":"Obes Res"},{"key":"6386_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.molmet.2018.05.003","volume":"13","author":"A Agrawal","year":"2018","unstructured":"Agrawal A, Parlee S, Perez-Tilve D, Li P, Pan J, Mroz PA, et al. Molecular elements in FGF19 and FGF21 defining KLB\/FGFR activity and specificity. Mol Metab. 2018;13:45\u201355.","journal-title":"Mol Metab"},{"key":"6386_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3892\/ijo.2016.3558","volume":"49","author":"N Pilco-Ferreto","year":"2016","unstructured":"Pilco-Ferreto N, Calaf GM. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016;49:753\u201362.","journal-title":"Int J Oncol"},{"key":"6386_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tips.2022.10.003","volume":"44","author":"L Wu","year":"2023","unstructured":"Wu L, Wang L, Du Y, Zhang Y, Ren J. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends Pharm Sci. 2023;44:34\u201349.","journal-title":"Trends Pharm Sci"},{"key":"6386_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-genet-102108-134850","volume":"43","author":"C Wang","year":"2009","unstructured":"Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu Rev Genet. 2009;43:95\u2013118.","journal-title":"Annu Rev Genet"},{"key":"6386_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(22)00375-2","volume":"8","author":"SMA Francque","year":"2023","unstructured":"Francque SMA, Dirinck E. NAFLD prevalence and severity in overweight and obese populations. Lancet Gastroenterol Hepatol. 2023;8:2\u20133.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6386_CR25","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.3390\/nu11123067","volume":"11","author":"L Recena Aydos","year":"2019","unstructured":"Recena Aydos L, Aparecida do Amaral L, Serafim de Souza R, Jacobowski AC, Freitas Dos Santos E, Rodrigues Macedo ML. Nonalcoholic fatty liver disease induced by high-fat diet in C57bl\/6 models. Nutrients. 2019;11:3067.","journal-title":"Nutrients"},{"key":"6386_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10555-022-10043-5","volume":"41","author":"EN Devericks","year":"2022","unstructured":"Devericks EN, Carson MS, McCullough LE, Coleman MF, Hursting SD. The obesity-breast cancer link: a multidisciplinary perspective. Cancer Metastasis Rev. 2022;41:607\u201325.","journal-title":"Cancer Metastasis Rev"},{"key":"6386_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s13679-019-00364-y","volume":"8","author":"GS Christodoulatos","year":"2019","unstructured":"Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M. The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep. 2019;8:413\u201333.","journal-title":"Curr Obes Rep"},{"key":"6386_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41366-019-0433-x","volume":"44","author":"MA van Baak","year":"2020","unstructured":"van Baak MA, Vink RG, Roumans NJT, Cheng CC, Adams AC, Mariman ECM. Adipose tissue contribution to plasma fibroblast growth factor 21 and fibroblast activation protein in obesity. Int J Obes (Lond). 2020;44:544\u20137.","journal-title":"Int J Obes (Lond)"},{"key":"6386_CR29","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.2337\/db14-0595","volume":"63","author":"KR Markan","year":"2014","unstructured":"Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014;63:4057\u201363.","journal-title":"Diabetes"},{"key":"6386_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28749-z","volume":"13","author":"D S\u00e1enz De Urturi","year":"2022","unstructured":"S\u00e1enz De Urturi D, Buqu\u00e9 X, Porteiro B, Folgueira C, Mora A, Delgado TC, et al. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis. Nat Commun. 2022;13:1096.","journal-title":"Nat Commun"},{"key":"6386_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","volume":"17","author":"Z Lin","year":"2013","unstructured":"Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013;17:779\u201389.","journal-title":"Cell Metab"},{"key":"6386_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1210\/me.2007-0313","volume":"22","author":"M Suzuki","year":"2008","unstructured":"Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, et al. \u03b2Klotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol. 2008;22:1006\u201314.","journal-title":"Mol Endocrinol"},{"key":"6386_CR33","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1073\/pnas.0701600104","volume":"104","author":"Y Ogawa","year":"2007","unstructured":"Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, et al. \u03b2Klotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA. 2007;104:7432\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6386_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"6386_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12:339.","journal-title":"Cell Death Dis"},{"key":"6386_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3389\/fonc.2020.00306","volume":"10","author":"I Mentoor","year":"2020","unstructured":"Mentoor I, Nell T, Emjedi Z, van Jaarsveld PJ, de Jager L, Engelbrecht AM. Decreased efficacy of doxorubicin corresponds with modifications in lipid metabolism markers and fatty acid profiles in breast tumors from obese vs. lean mice. Front Oncol. 2020;10:306.","journal-title":"Front Oncol"},{"key":"6386_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/sj.bjc.6604166","volume":"98","author":"ME Grossmann","year":"2008","unstructured":"Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer. 2008;98:370\u20139.","journal-title":"Br J Cancer"},{"key":"6386_CR38","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1080\/15548627.2017.1332565","volume":"13","author":"SJ Chung","year":"2017","unstructured":"Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, et al. ADIPOQ\/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11\/LKB1-mediated activation of the AMPK-ULK1 axis. Autophagy. 2017;13:1386\u2013403.","journal-title":"Autophagy"},{"key":"6386_CR39","first-page":"574","volume":"7","author":"Z Liu","year":"2017","unstructured":"Liu Z, Shi A, Song D, Han B, Zhang Z, Ma L, et al. Resistin confers resistance to doxorubicin-induced apoptosis in human breast cancer cells through autophagy induction. Am J Cancer Res. 2017;7:574\u201383.","journal-title":"Am J Cancer Res"},{"key":"6386_CR40","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.3390\/ijms21113794","volume":"21","author":"CC Lipsey","year":"2020","unstructured":"Lipsey CC, Harbuzariu A, Robey RW, Huff LM, Gottesman MM, Gonzalez-Perez RR. Leptin signaling affects survival and chemoresistance of estrogen receptor negative breast cancer. Int J Mol Sci. 2020;21:3794.","journal-title":"Int J Mol Sci"},{"key":"6386_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02677-9","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Wu G, Fang Q, Zhang M, Hui X, Sheng B, et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat Commun. 2018;9:272.","journal-title":"Nat Commun"},{"key":"6386_CR42","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.xpro.2020.100222","volume":"1","author":"Y Jung","year":"2020","unstructured":"Jung Y, Zhao M, Svensson KJ. Isolation, culture, and functional analysis of hepatocytes from mice with fatty liver disease. STAR Protoc. 2020;1:100222.","journal-title":"STAR Protoc"},{"key":"6386_CR43","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.xpro.2020.100086","volume":"1","author":"M Charni-Natan","year":"2020","unstructured":"Charni-Natan M, Goldstein I. Protocol for primary mouse hepatocyte isolation. STAR Protoc. 2020;1:100086.","journal-title":"STAR Protoc"},{"key":"6386_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genom Proteom Bioinforma. 2022;20:587\u201396.","journal-title":"Genom Proteom Bioinforma"},{"key":"6386_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04175-w","volume":"7","author":"JY Kim","year":"2017","unstructured":"Kim JY, Lee HJ, Lee S-J, Jung YH, Yoo DY, Hwang IK, et al. Palmitic Acid\u2013BSA enhances Amyloid-\u03b2 production through GPR40-mediated dual pathways in neuronal cells: Involvement of the Akt\/mTOR\/HIF-1\u03b1 and Akt\/NF-\u03baB pathways. Sci Rep. 2017;7:4335.","journal-title":"Sci Rep"},{"key":"6386_CR46","doi-asserted-by":"crossref","unstructured":"Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, et al. GenBank. Nucleic Acids Res 2013, 41(Database issue): D36\u201342.","DOI":"10.1093\/nar\/gks1195"},{"key":"6386_CR47","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41587-021-01156-3","volume":"40","author":"F Teufel","year":"2022","unstructured":"Teufel F, Almagro Armenteros JJ, Johansen AR, G\u00edslason MH, Pihl SI, Tsirigos KD, et al. SignalP 6.0 predicts all five types of signal peptides using protein language models. Nat Biotechnol. 2022;40:1023\u20135.","journal-title":"Nat Biotechnol"},{"key":"6386_CR48","doi-asserted-by":"crossref","first-page":"1.30.31","DOI":"10.1002\/cpbi.5","volume":"54","author":"G Stelzer","year":"2016","unstructured":"Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinforma. 2016;54:1.30.31\u201331.30.33.","journal-title":"Curr Protoc Bioinforma"},{"key":"6386_CR49","doi-asserted-by":"publisher","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","volume":"51","author":"TU Consortium","year":"2022","unstructured":"Consortium TU. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2022;51:D523\u2013D531.","journal-title":"Nucleic Acids Res"},{"key":"6386_CR50","unstructured":"\u201cFour parameter logistic curve\u201d online data analysis tool. https:\/\/www.myassays.com\/how-to-reference-myassays.html#:~:text=You%20can%20refer%20to%20MyAssays,and%20the%20relevant%20assay%20link Accessed 25 Feb 2023."},{"key":"6386_CR51","unstructured":"FlowJo\u2122 software [software application] version 10.7.1. Ashland, OB: Dickinson and Company; https:\/\/www.flowjo.com\/citing-flowjo 2023."},{"key":"6386_CR52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cyto.a.20273","volume":"69","author":"CB Campos","year":"2006","unstructured":"Campos CB, Paim BA, Cosso RG, Castilho RF, Rottenberg H, Vercesi AE. Method for monitoring of mitochondrial cytochrome c release during cell death: immunodetection of cytochrome c by flow cytometry after selective permeabilization of the plasma membrane. Cytometry Part A. 2006;69:515\u201323.","journal-title":"Cytometry Part A"},{"key":"6386_CR53","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.cdd.4401263","volume":"10","author":"NJ Waterhouse","year":"2003","unstructured":"Waterhouse NJ, Trapani JA. A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ. 2003;10:853\u20135.","journal-title":"Cell Death Differ"},{"key":"6386_CR54","unstructured":"IBM Corp. Released 2017. IBM SPSS statistics for windows VA. Armonk, NY: IBM Corp.; 2017."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06386-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T04:00:25Z","timestamp":1731038425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06386-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["6386"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06386-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2761258\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments conducted in this study were performed following the guidelines and regulations set forth by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong (no. 4483-17, 5895-21). For the collection of clinical\u2013pathological characteristics, informed consent was obtained from the patients for research purposes. The procedures involving human subjects were reviewed and approved by the institutional review board with approval no. SZR2019-78. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"67"}}